Clinical trial NCT01579318: Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma
Official title: A Multicenter Phase II Trial of Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Cutaneous T Cell Lymphomas (CTCL)
Mycosis Fungoides (MF)
Lead sponsor: OncoSec Medical Incorporated
Sponsor class: INDUSTRY
First posted: 2012-04-17
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A single arm, open label, multi-center, phase 2 study to assess the safety and anti-tumor activity of ImmunoPulse IL-12® in participants with stage IB to IIIB mycosis fungoides. ImmunPulseIL12® is the combination of intrtumoral interleukin-12 gene (also known as tavokinogene telseplasmid \[tavo\]) and in vivo electroporation-mediated plasmid deoxyribonucleic acid \[DNA\] vaccine therapy (tavo-EP) administered using the OncoSec Medical System (OMS).

All participants may receive up to four cycles of treatment consisting of three treatment days, Days 1, 5 and 8, in a 12-week cycle as per Protocol version 6 (see Limitations and Caveats section of this record for protocol version information). Patients will receive intra-tumoral injection of tavo at a concentration of 1.0 mg/mL (maximum volume of 1 mL/day distributed over 2-4 lesions), followed immediately by electrical discharge around the tumor site resulting in electroporation of plasmid deoxyribonucleic acid (DNA) into tumor cells.

Detailed description: This is a single arm, open label, multi-center phase 2 study to assess the safety and anti-tumor activity of intratumoral tavo electroporation in participants with stage IB to IIIB mycosis fungoides. All participants received up to four cycles of treatment consisting of three treatment days, Days 1, 5 and 8, in a 12-week cycle. Patients will receive intra-tumoral injection of tavo at a concentration of 1.0 mg/mL (maximum volume of 1 mL/day distributed over 2-4 lesions), followed immediately by electrical discharge around the tumor site resulting in electroporation of plasmid deoxyribonucleic acid (DNA) into tumor cells. Prior to the first cycle of treatment, the investigator will select at least one lesion, or affected area in erythrodermic patients, to be left untreated for the duration of the study to allow for clinical observation of an untreated site. Participants will be followed for safety and clinical evaluation every 4 weeks. Quality of Life will be assessed using the Skindex29, Functional Assessment of Cancer Therapy - General (FACT-G) and Visual Analog Scale for Pruritus (VAS-P) instruments. Survival follow up will occur at 3-month intervals over 2 years following end of study.

Eligibility criteria: Inclusion Criteria

1. Biopsy confirmed mycosis fungoides of stage IB - IIIB;
2. Participants must have failed or have been intolerant to at least one standard of care therapy;
3. Participants must have a minimum of one lesion, or affected area in erythrodermic patients (T4/stage III), that meets all following criteria:

   * Accessible for pIL-12 electroporation;
   * Adequate size such that 6-mm biopsy can be collected prior to treatment;
4. Participants must have one additional lesion, or affected area in erythrodermic patients, that remains untreated for the duration of the study;
5. Age ≥ 18 years old;
6. Participants must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2;
7. Required wash out period of 4 weeks from last dose for the following prior therapies:

   * Topical therapy;
   * Radiotherapy (including photo therapy);
   * Multi-agent chemotherapy;
   * Systemic biological therapy;
   * Histone deacetylase inhibitors (HDAC) inhibitors;
   * Interferon alpha and other investigational therapies;
8. For women of childbearing potential, negative pregnancy serum test within 14 days to the first study drug administration, and use of birth control from 30 days prior to the first day study drug administration and 30 days following last day study drug administration;
9. Male participants must be surgically sterile, or must agree to use contraception during the study and at least 30 days following the last day of study drug administration.
10. Life expectancy of at least 6 months;
11. The patient must have adequate renal and hepatic function as assessed by standard laboratory criteria within 4 weeks prior to enrollment:

    * Creatinine \< 2 x upper limit of normal (ULN);
    * Serum bilirubin within institutional normal limits;
    * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 1.5 x ULN;
    * Absolute neutrophil count (ANC) \> 1000/mm;
    * Platelet count \> 100,000 /mm;
12. Able to give informed consent and able to follow guidelines given in the study.

Exclusion Criteria

1. Prior therapy with IL-12 or prior gene therapy;
2. Prior treatment with Campath (alemtuzumab) within 1 year of enrollment;
3. Concurrent immunotherapy, chemotherapy, or radiation therapy for duration of patient participation on study;
4. Concurrent steroid therapy;
5. Concurrent anticoagulant therapy (acetylsalicylic acid \[ASA\]≤ 325mg/day allowed);
6. Evidence of significant active infection (e.g., pneumonia, cellulitis, wound abscess, etc.) at time of study enrollment;
7. Patients with current evidence of large cell transformation (LCT) with aggressive disease at study entry (patients with a history of LCT are eligible if pathologic evidence at study entry indicates there is no presence of LCT);
8. Known history of human immunodeficiency virus (HIV), Human T-cell leukemia virus (HTLV) -1/2 infection, hepatitis B or hepatitis C (active, prior treatment, or both);
9. No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 2 years;
10. Significant cardiovascular disease (i.e. New York Heart Association \[NYHA\] class 3 congestive heart failure; myocardial infarction within the past 6 months; unstable angina; coronary angioplasty with the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias);
11. Any other medical history, including laboratory results, deemed by the investigator to be likely to interfere with patient's participation in the study, or to interfere with the interpretation of the results;
12. Participants with electronic pacemakers or defibrillators are excluded from this study as the effect of electroporation on these devices is unknown;
13. Pregnant and breast-feeding women are excluded from the study as effects on the fetus are unknown and there may be a risk of increased fetal wastage.

Primary outcomes:
measure: Objective Response Rate Assessed by Modified Severity Weighted Assessment Tool (mSWAT) Score in the Skin
timeFrame: Every 28 days for the first 24-weeks of treatment
measure: Objective Response Rate Assessed by Modified Severity Weighted Assessment Tool (mSWAT) Composite Global Score
timeFrame: Every 28 days for the first 24-weeks of treatment
Secondary outcomes:
measure: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
timeFrame: From the start of study treatment up to 340 days
measure: Duration of Overall Objective Response Assessed by mSWAT Skin Score
timeFrame: From first documented response until disease progression (Up to 340 days)
measure: Time to Overall Objective Response Assessed by mSWAT Skin Score
timeFrame: From start of study treatment until overall objective response (Up to 340 days)
measure: Quality of Life (QoL)
timeFrame: Every 28 days for up to 340 days
Other outcomes:
measure: Immunologic Effects of IL-12 Plasmid Electroporation in Tissue
timeFrame: 2 years
measure: Immunologic Effects of IL-12 Plasmid Electroporation in Peripheral Blood
timeFrame: 2 years
Locations:
city: San Francisco
country: United States
facility: UCSF Helen Diller Comprehensive Cancer Center
state: California
Study officials:
References: